{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:14:31Z","timestamp":1789470871729,"version":"build-2803163510"},"reference-count":86,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Factor VIII (FVIII) inhibitor formation is a major clinical concern during replacement therapy in patients with hemophilia A. Immune tolerance induction (ITI) is the only therapeutic approach to attempt inhibitor eradication and establishment of long-term immune tolerance to FVIII. Hemophilia Inhibitor Previously Untreated Patient (PUP) Study (HIPS) was a prospective clinical trial to investigate changes in the immune system of PUPs with severe hemophilia A. Five patients who developed persistent FVIII inhibitors during HIPS entered an ITI extension arm (HIPS-ITI). During HIPS-ITI, inhibitor patients received ITI with the same FVIII product (a single source of recombinant, human full-length FVIII) used in HIPS until successful tolerance, declared failure, or a maximum of 2 years after HIPS-ITI enrollment, whichever came first. Blood samples and clinical data were collected monthly. Longitudinal FVIII-binding antibody signatures, associated binding specificities, and apparent affinities were determined for each patient at each sampling time point. ITI was successful or partially successful in 2 patients and failed in 3. Both groups presented with distinct FVIII-specific antibody signatures. ITI success required the disappearance of FVIII inhibitors, which was associated with the eradication or sustained titer minimization of high-affinity FVIII-specific antibodies, particularly of the immunoglobulin G1 (IgG1) and IgG4 subclasses. In contrast, ITI failure, as reflected by FVIII inhibitor persistence, was associated with persistent high-affinity FVIII-specific antibodies. Interestingly, 1 patient with partial ITI success and 1 patient with ITI failure developed apparent oligoreactive FVIII-binding antibodies during ITI. The explanation of the true nature of these antibodies requires more comprehensive follow-ups in future studies. This trial was registered at www.clinicaltrials.gov as #NCT01652027.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007267","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T19:33:12Z","timestamp":1662665592000},"page":"1831-1848","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3217-4454","authenticated-orcid":false,"given":"Helmut","family":"Paul","sequence":"first","affiliation":[{"name":"1Institute Krems Bioanalytics, IMC University of Applied Sciences Krems, Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3246-2317","authenticated-orcid":false,"given":"Verena","family":"Berg","sequence":"additional","affiliation":[{"name":"1Institute Krems Bioanalytics, IMC University of Applied Sciences Krems, Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bagirath","family":"Gangadharan","sequence":"additional","affiliation":[{"name":"2Baxalta Innovations GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Bowen","sequence":"additional","affiliation":[{"name":"3Indiana Hemophilia and Thrombosis Center Inc., Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"LeBeau","sequence":"additional","affiliation":[{"name":"4Rho Inc., Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6261-9157","authenticated-orcid":false,"given":"Jan","family":"Blatn\u00fd","sequence":"additional","affiliation":[{"name":"5Department of Paediatric Haematology, University Hospital Brno, Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-6421","authenticated-orcid":false,"given":"Christoph","family":"Male","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-5185","authenticated-orcid":false,"given":"Vlad C.","family":"Radulescu","sequence":"additional","affiliation":[{"name":"7Hemophilia Treatment Center, University of Kentucky, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Diaz","sequence":"additional","affiliation":[{"name":"8Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-4028","authenticated-orcid":false,"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[{"name":"9IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy"},{"name":"10Fondazione Ca\u2019 Granda, Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5232-0477","authenticated-orcid":false,"given":"Deborah L.","family":"Brown","sequence":"additional","affiliation":[{"name":"11University of Texas Health Science Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-4610","authenticated-orcid":false,"given":"Birgit M.","family":"Reipert","sequence":"additional","affiliation":[{"name":"1Institute Krems Bioanalytics, IMC University of Applied Sciences Krems, Krems, Austria"},{"name":"2Baxalta Innovations GmbH, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"3","key":"2023050514193276700_bib1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2023050514193276700_bib2","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A\u00a0randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023050514193276700_bib3","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"issue":"7","key":"2023050514193276700_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group","volume":"328","author":"Lusher","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023050514193276700_bib5","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH11-09-0642","article-title":"Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A","volume":"107","author":"Auerswald","year":"2012","journal-title":"Thromb Haemost"},{"issue":"1","key":"2023050514193276700_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"issue":"9","key":"2023050514193276700_bib7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023050514193276700_bib8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/hae.13534","article-title":"Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII","volume":"24","author":"Carpenter","year":"2018","journal-title":"Haemophilia"},{"issue":"2","key":"2023050514193276700_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.12091","article-title":"Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization","volume":"160","author":"Collins","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"2023050514193276700_bib10","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.transci.2019.08.008","article-title":"Hemophilia A with inhibitor: immune tolerance induction (ITI) in the mirror of time","volume":"58","author":"Nakar","year":"2019","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"2023050514193276700_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/joim.12301","article-title":"Inhibitors in haemophilia: what have we learned from registries? A systematic review","volume":"277","author":"Osooli","year":"2015","journal-title":"J\u00a0Intern Med"},{"issue":"6","key":"2023050514193276700_bib12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2023050514193276700_bib13","first-page":"559","article-title":"US guidelines for immune tolerance induction in patients with haemophilia A and inhibitors Haemophilia","volume":"21","author":"Valentino","year":"2015","journal-title":""},{"issue":"4","key":"2023050514193276700_bib14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.15053","article-title":"How I manage patients with inherited haemophilia A and B and factor inhibitors","volume":"180","author":"Ljung","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2023050514193276700_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/hae.14431","article-title":"Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors","volume":"28","author":"Di Minno","year":"2022","journal-title":"Haemophilia"},{"issue":"5","key":"2023050514193276700_bib16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2012.01754.x","article-title":"Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice","volume":"88","author":"Benson","year":"2012","journal-title":"Eur J Haematol"},{"issue":"3","key":"2023050514193276700_bib17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2516.2002.00626.x","article-title":"Inhibitors: resolving diagnostic and therapeutic dilemmas","volume":"8","author":"Dimichele","year":"2002","journal-title":"Haemophilia"},{"issue":"Suppl 3","key":"2023050514193276700_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13445","article-title":"Immune tolerance induction: what have we learned over time?","volume":"24","author":"Brackmann","year":"2018","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"2023050514193276700_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1365-2516.2000.00045.x","article-title":"Inhibitors in haemophilia: a primer","volume":"6","author":"DiMichele","year":"2000","journal-title":"Haemophilia"},{"issue":"1","key":"2023050514193276700_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2006.06359.x","article-title":"Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors","volume":"136","author":"Reipert","year":"2007","journal-title":"Br J Haematol"},{"issue":"10","key":"2023050514193276700_bib21","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1182\/blood-2005-03-1182","article-title":"High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors","volume":"106","author":"Hausl","year":"2005","journal-title":"Blood"},{"issue":"102","key":"2023050514193276700_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2516.2008.01962.x","article-title":"Modulation of factor VIII-specific memory B cells","volume":"16","author":"Reipert","year":"2010","journal-title":"Haemophilia"},{"issue":"11","key":"2023050514193276700_bib23","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1111\/j.1538-7836.2007.02736.x","article-title":"Factor VIII-specific memory B cells in patients with hemophilia A","volume":"5","author":"van Helden","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2023050514193276700_bib24","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.4049\/jimmunol.172.10.5900","article-title":"Generation of anergic and regulatory T cells following prolonged exposure to a harmless antigen","volume":"172","author":"Chen","year":"2004","journal-title":"J\u00a0Immunol"},{"issue":"10","key":"2023050514193276700_bib25","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1084\/jem.20040249","article-title":"In\u00a0vivo instruction of suppressor commitment in naive T cells","volume":"199","author":"Apostolou","year":"2004","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"2023050514193276700_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.blre.2018.02.003","article-title":"Review of immune tolerance induction in hemophilia A","volume":"32","author":"Schep","year":"2018","journal-title":"Blood Rev"},{"issue":"2","key":"2023050514193276700_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1471-4906(02)00035-2","article-title":"Will the idiotypic network help to solve natural tolerance?","volume":"24","author":"Coutinho","year":"2003","journal-title":"Trends Immunol"},{"issue":"4","key":"2023050514193276700_bib28","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1172\/JCI117489","article-title":"Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies","volume":"94","author":"Gilles","year":"1994","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"2023050514193276700_bib29","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1172\/JCI118558","article-title":"Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A","volume":"97","author":"Gilles","year":"1996","journal-title":"J\u00a0Clin Invest"},{"issue":"1 suppl 1","key":"2023050514193276700_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.seminhematol.2003.11.016","article-title":"Environmental and genetic factors influencing inhibitor development","volume":"41","author":"Oldenburg","year":"2004","journal-title":"Semin Hematol"},{"issue":"12","key":"2023050514193276700_bib31","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"2023050514193276700_bib32","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2023050514193276700_bib33","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1111\/j.1365-2516.2011.02739.x","article-title":"Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database","volume":"18","author":"Carpenter","year":"2012","journal-title":"Haemophilia"},{"issue":"1","key":"2023050514193276700_bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1365-2516.1998.0146c.x","article-title":"Inhibitors occur more frequently in African-American and Latino haemophiliacs","volume":"4","author":"Aledort","year":"1998","journal-title":"Haemophilia"},{"issue":"16","key":"2023050514193276700_bib35","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMoa075760","article-title":"Inhibitors of factor VIII in black patients with hemophilia","volume":"360","author":"Viel","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"102","key":"2023050514193276700_bib36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2516.2008.01923.x","article-title":"Inhibitor development: patient-determined risk factors","volume":"16","author":"Astermark","year":"2010","journal-title":"Haemophilia"},{"issue":"2","key":"2023050514193276700_bib37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2516.2010.02422.x","article-title":"Treatment related factors and inhibitor development in children with severe haemophilia A","volume":"17","author":"Maclean","year":"2011","journal-title":"Haemophilia"},{"issue":"10","key":"2023050514193276700_bib38","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1111\/j.1538-7836.2011.04467.x","article-title":"Surgery and inhibitor development in hemophilia A: a systematic review","volume":"9","author":"Eckhardt","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2023050514193276700_bib39","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/j.1365-2516.2011.02659.x","article-title":"Early prophylaxis\/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience","volume":"18","author":"Auerswald","year":"2012","journal-title":"Haemophilia"},{"issue":"5","key":"2023050514193276700_bib40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/hae.13075","article-title":"Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models","volume":"22","author":"L\u00f6vgren","year":"2016","journal-title":"Haemophilia"},{"key":"2023050514193276700_bib41","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating factor VIII: recent progress","volume":"10","author":"Lacroix-Desmazes","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"2023050514193276700_bib42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/17474086.2019.1604213","article-title":"An update on the \u2018danger theory\u2019 in inhibitor development in hemophilia A","volume":"12","author":"Schep","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2023050514193276700_bib43","first-page":"612","article-title":"Proceedings: A more uniform measurement of factor VIII inhibitors","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb Diath Haemorrh"},{"issue":"2","key":"2023050514193276700_bib44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb Haemost"},{"issue":"2","key":"2023050514193276700_bib45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/hae.13424","article-title":"Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review","volume":"24","author":"Miller","year":"2018","journal-title":"Haemophilia"},{"issue":"6","key":"2023050514193276700_bib46","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2023050514193276700_bib47","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2023050514193276700_bib48","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2016-06-720086","article-title":"Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A","volume":"129","author":"Cannavo","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2023050514193276700_bib49","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood-2008-08-174987","article-title":"Quantitation of anti-factor VIII antibodies in human plasma","volume":"113","author":"Krudysz-Amblo","year":"2009","journal-title":"Blood"},{"issue":"suppl 1","key":"2023050514193276700_bib50","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2019-124743","article-title":"Neutralizing and non-neutralizing anti-FVIII antibodies in black and white hemophilia A subjects: a natural history profile","volume":"134","author":"Pratt","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2023050514193276700_bib51","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/bloodadvances.2021005745","article-title":"Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors","volume":"6","author":"Schweiger","year":"2022","journal-title":"Blood Adv"},{"issue":"22","key":"2023050514193276700_bib52","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","article-title":"The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development","volume":"4","author":"Reipert","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2023050514193276700_bib53","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.2194","article-title":"B\u00a0cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen","volume":"13","author":"Puga","year":"2011","journal-title":"Nat Immunol"},{"issue":"1","key":"2023050514193276700_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/76882","article-title":"Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response","volume":"1","author":"Guinamard","year":"2000","journal-title":"Nat Immunol"},{"key":"2023050514193276700_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1034\/j.1600-065X.2003.00058.x","article-title":"Extrafollicular antibody responses","volume":"194","author":"MacLennan","year":"2003","journal-title":"Immunol Rev"},{"issue":"2","key":"2023050514193276700_bib56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1615\/CritRevImmunol.2018024985","article-title":"Heterogeneity of memory marginal zone B cells","volume":"38","author":"Hendricks","year":"2018","journal-title":"Crit Rev Immunol"},{"issue":"1","key":"2023050514193276700_bib57","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/imr.12754","article-title":"The continuing story of T-cell independent antibodies","volume":"288","author":"Allman","year":"2019","journal-title":"Immunol Rev"},{"issue":"7","key":"2023050514193276700_bib58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/ni.2914","article-title":"CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype","volume":"15","author":"Zuccarino-Catania","year":"2014","journal-title":"Nat Immunol"},{"issue":"4","key":"2023050514193276700_bib59","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/ni1440","article-title":"FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis","volume":"8","author":"Xiang","year":"2007","journal-title":"Nat Immunol"},{"issue":"3","key":"2023050514193276700_bib60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2023050514193276700_bib61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.immuni.2018.06.007","article-title":"LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells","volume":"49","author":"Lino","year":"2018","journal-title":"Immunity"},{"issue":"6","key":"2023050514193276700_bib62","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.immuni.2014.10.016","article-title":"Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation","volume":"41","author":"Matsumoto","year":"2014","journal-title":"Immunity"},{"issue":"6","key":"2023050514193276700_bib63","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.immuni.2017.11.022","article-title":"CCR6 defines memory B cell precursors in mouse and human germinal centers, revealing light-zone location and predominant low antigen affinity","volume":"47","author":"Suan","year":"2017","journal-title":"Immunity"},{"issue":"4","key":"2023050514193276700_bib64","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.it.2019.01.012","article-title":"Programming isotype-specific plasma cell function","volume":"40","author":"Higgins","year":"2019","journal-title":"Trends Immunol"},{"issue":"4","key":"2023050514193276700_bib65","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bj.2019.05.008","article-title":"Regulatory functions of B cells and regulatory plasma cells","volume":"42","author":"Fillatreau","year":"2019","journal-title":"Biomed J"},{"issue":"6","key":"2023050514193276700_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells10061508","article-title":"The bone marrow as sanctuary for plasma cells and memory T-cells: implications for adaptive immunity and vaccinology","volume":"10","author":"Slamanig","year":"2021","journal-title":"Cells"},{"issue":"1","key":"2023050514193276700_bib67","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.13013","article-title":"Plasma cell survival: the intrinsic drivers, migratory signals, and extrinsic regulators","volume":"303","author":"Nguyen","year":"2021","journal-title":"Immunol Rev"},{"key":"2023050514193276700_bib68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/bs.ai.2020.01.002","article-title":"Unraveling the mysteries of plasma cells","volume":"146","author":"Schuh","year":"2020","journal-title":"Adv Immunol"},{"key":"2023050514193276700_bib69","author":"Committee for Medicinal Products for Human Use","year":"2017"},{"key":"2023050514193276700_bib70","author":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance Document","year":"2019"},{"issue":"4","key":"2023050514193276700_bib71","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2004.02.004","article-title":"Polyreactivity of antibody molecules","volume":"25","author":"Notkins","year":"2004","journal-title":"Trends Immunol"},{"issue":"7","key":"2023050514193276700_bib72","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/(SICI)1521-4141(199807)28:07<2108::AID-IMMU2108>3.0.CO;2-R","article-title":"Hidden anti-phospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments","volume":"28","author":"Cabiedes","year":"1998","journal-title":"Eur J Immunol"},{"issue":"2","key":"2023050514193276700_bib73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/jaut.2000.0472","article-title":"Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents","volume":"16","author":"Bouvet","year":"2001","journal-title":"J\u00a0Autoimmun"},{"issue":"1-2","key":"2023050514193276700_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(00)00196-4","article-title":"Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH","volume":"241","author":"McMahon","year":"2000","journal-title":"J\u00a0Immunol Methods"},{"issue":"14","key":"2023050514193276700_bib75","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1111\/j.1742-4658.2010.07714.x","article-title":"Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis","volume":"277","author":"Djoumerska-Alexieva","year":"2010","journal-title":"FEBS J"},{"issue":"6","key":"2023050514193276700_bib76","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1089\/ars.2007.2007","article-title":"Reactive oxygen species and endothelial activation","volume":"10","author":"Alom-Ruiz","year":"2008","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"2023050514193276700_bib77","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1074\/jbc.M509190200","article-title":"Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G","volume":"281","author":"Dimitrov","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"2023050514193276700_bib78","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0891-5849(88)90026-3","article-title":"Superoxide dependent iron release from ferritin in inflammatory diseases","volume":"4","author":"Biemond","year":"1988","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2023050514193276700_bib79","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0003-9861(91)90266-L","article-title":"Ferrous iron release from transferrin by human neutrophil-derived superoxide anion: effect of pH and iron saturation","volume":"284","author":"Brieland","year":"1991","journal-title":"Arch Biochem Biophys"},{"issue":"37","key":"2023050514193276700_bib80","doi-asserted-by":"crossref","first-page":"26696","DOI":"10.1074\/jbc.M702751200","article-title":"Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions","volume":"282","author":"Dimitrov","year":"2007","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"2023050514193276700_bib81","doi-asserted-by":"crossref","first-page":"993","DOI":"10.4049\/jimmunol.1300880","article-title":"Antibody polyreactivity in health and disease: Statu variabilis","volume":"191","author":"Dimitrov","year":"2013","journal-title":"J\u00a0Immunol"},{"issue":"10","key":"2023050514193276700_bib82","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2023050514193276700_bib83","doi-asserted-by":"crossref","first-page":"17767","DOI":"10.1074\/jbc.M114.556266","article-title":"A\u00a0cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism","volume":"289","author":"Dimitrov","year":"2014","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"2023050514193276700_bib84","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molmed.2016.01.004","article-title":"Heme: modulator of plasma systems in hemolytic diseases","volume":"22","author":"Roumenina","year":"2016","journal-title":"Trends Mol Med"},{"issue":"6","key":"2023050514193276700_bib85","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.immuni.2020.10.005","article-title":"Polyreactive broadly neutralizing B cells are selected to provide defense against pandemic threat influenza viruses","volume":"53","author":"Guthmiller","year":"2020","journal-title":"Immunity"},{"key":"2023050514193276700_bib86","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cellimm.2018.01.008","article-title":"Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A","volume":"325","author":"Peyron","year":"2018","journal-title":"Cell Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1831\/2049115\/blooda_adv-2022-007267-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1831\/2049115\/blooda_adv-2022-007267-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T14:22:10Z","timestamp":1683296530000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/9\/1831\/486551\/Prospective-Hemophilia-Inhibitor-PUP-Study-reveals"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":86,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,5,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007267","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]}}}